Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients
- PMID: 20078618
- PMCID: PMC2830603
- DOI: 10.1111/j.1365-2125.2009.03555.x
Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients
References
-
- Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999;36:99–114. - PubMed
-
- Alexandre J, Rey E, Girre V, Grabar S, Tran A, Montheil V, Rabillon F, Dieras V, Jullien V, Herait P, Pons G, Treluyer JM, Goldwasser F. Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann Oncol. 2007;18:168–72. - PubMed
-
- Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53:4–9. - PubMed
-
- Lim ST, Tupule A, Espina BM, Levine AM. Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer. 2005;103:417–21. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical